Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00239109 |
Likewise, adiponectine, secreted from adipocytes and a possible link between obesity and insulin resistance will be determined; recent studies show an adiponectine decrease in humans with insulin resistance and obesity; furthermore, prospective studies have shown these changes could predict a higher risk of DM development.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Ziprasidone Drug: Olanzapine Procedure: Scales Procedure: measures of the body (Weight...) Procedure: Serum analysis |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety Study |
Official Title: | Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study. |
Estimated Enrollment: | 112 |
Study Start Date: | April 2003 |
Estimated Study Completion Date: | February 2007 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Spain | |
Pfizer Investigational Site | |
BADAJOZ, Spain | |
Pfizer Investigational Site | |
BARCELONA, Spain | |
Pfizer Investigational Site | |
MADRID, Spain | |
Pfizer Investigational Site | |
SEVILLA, Spain | |
Pfizer Investigational Site | |
Salamanca, Spain | |
Pfizer Investigational Site | |
Zamora, Spain | |
Spain, VIZCAYA | |
Pfizer Investigational Site | |
BILBAO, VIZCAYA, Spain | |
Spain, Vizcaya | |
Pfizer Investigational Site | |
Bilbao, Vizcaya, Spain |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A1281064 |
Study First Received: | October 12, 2005 |
Last Updated: | March 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00239109 History of Changes |
Health Authority: | Spain: Ministry of Health and Consumption |
Neurotransmitter Agents Tranquilizing Agents Olanzapine Psychotropic Drugs Antiemetics Central Nervous System Depressants Antipsychotic Agents Serotonin Uptake Inhibitors Serotonin |
Schizophrenia Dopamine Mental Disorders Dopamine Agents Psychotic Disorders Peripheral Nervous System Agents Ziprasidone Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Olanzapine Antiemetics Schizophrenia Serotonin Antagonists Mental Disorders Therapeutic Uses Schizophrenia and Disorders with Psychotic Features Tranquilizing Agents |
Gastrointestinal Agents Central Nervous System Depressants Dopamine Antagonists Antipsychotic Agents Serotonin Uptake Inhibitors Pharmacologic Actions Serotonin Agents Autonomic Agents Dopamine Agents Peripheral Nervous System Agents Ziprasidone Central Nervous System Agents |